Profil

Berger Manon

Département de pharmacie > Développement de nanomédicaments

CIRM

See author's contact details
ORCID
0000-0001-7237-8246
Main Referenced Co-authors
Piel, Géraldine  (20)
Lechanteur, Anna  (18)
Evrard, Brigitte  (15)
Debuigne, Antoine  (13)
Toussaint, François  (13)
Main Referenced Keywords
protein corona (7); biomaterial (5); nanomedicine (5); Lipoplexes (4); lipid-PEG (3);
Main Referenced Unit & Research Centers
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège [BE] (8)
CESAM - Complex and Entangled Systems from Atoms to Materials - ULiège [BE] (4)
Center for Education and Research on Macromolecules (CERM) (4)
Center for Interdisciplinary Research on Medicines (CIRM) (2)
Complex and Entangled Systems from Atoms to Materials (CESAM) Research Unit (2)
Main Referenced Disciplines
Pharmacy, pharmacology & toxicology (17)
Chemistry (6)
Materials science & engineering (5)
Biotechnology (1)

Publications (total 21)

The most downloaded
64 downloads
Degey, M., Berger, M., Evrard, B., & Piel, G. (31 January 2024). New amphiphilic polymers with variable length and number of lipid chains as alternatives to PEG for the formulation of lipid nanoparticles encapsulating siRNA [Poster presentation]. CIRM DAY - Scientific day, Liege, Belgium. https://hdl.handle.net/2268/312600

The most cited

19 citations (Scopus®)

Berger, M., Lechanteur, A., Evrard, B., & Piel, G. (2021). Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now? International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2021.120851 https://hdl.handle.net/2268/261980

Degey, M., Berger, M., Evrard, B., & Piel, G. (10 April 2024). Exploring alternatives to PEG for the formulation of lipid nanoparticles encapsulating siRNA [Poster presentation]. 17th European Symposium on Controlled Drug Delivery.

Degey, M., Berger, M., Evrard, B., & Piel, G. (31 January 2024). New amphiphilic polymers with variable length and number of lipid chains as alternatives to PEG for the formulation of lipid nanoparticles encapsulating siRNA [Poster presentation]. CIRM DAY - Scientific day, Liege, Belgium.

Berger, M.* , Toussaint, F.* , Djemaa, S. B.* , Maquoi, E., Pendeville-Samain, H., Evrard, B., Jérôme, C., Chain, J. L., Lechanteur, A., Mottet, D.* , Debuigne, A.* , & Piel, G.*. (2023). Poly(N-methyl‐N‐vinylacetamide): a strong alternative to PEG for lipid‐based nanocarriers delivering siRNA. Advanced Healthcare Materials, 2302712. doi:10.1002/adhm.202302712
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Berger, M. (2023). Development of lipid nanoparticles based on PEG alternatives for efficient siRNA delivery [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/307614

Berger, M.* , Toussaint, F.* , Djemaa, S. B.* , Laloy, J., Pendeville-Samain, H., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D.* , Debuigne, A.* , & Piel, G.*. (02 August 2023). Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery. Journal of Controlled Release, 361, 87 - 101. doi:10.1016/j.jconrel.2023.07.031
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (27 April 2023). Effect of PEG anchor and serum on Lipid Nanoparticles: development of a nanoparticle tracking method [Paper presentation]. 21st Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (21 March 2023). Impact of the hydrophobic chain length of PEG derivatives on the behavior of LNPs in serum: Development of a Nanoparticle Tracking Analysis (NTA) Method [Poster presentation]. 4th European Conference on Pharmaceutics, Marseille, France.
Peer reviewed

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (10 February 2023). Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method. Pharmaceutics, 15 (2). doi:10.3390/pharmaceutics15020597
Peer Reviewed verified by ORBi

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (01 February 2023). Effect of PEG anchor and serum on Lipid Nanoparticles: development of a nanoparticles tracking method [Paper presentation]. CIRM Day, Liege, Belgium.

Debuigne, A., Piel, G., Mottet, D., Toussaint, F., Berger, M., Ben Djemaa, S., & Lechanteur, A. (2023). Polymer Derivative and their use as lipid nanoparticle modifiers”.

Toussaint, F., Berger, M., Lechanteur, A., Jérôme, C., Piel, G., & Debuigne, A. (15 November 2022). Amphiphilic poly(N-vinylpyrrolidone)-based lipoplex modifiers for drug delivery applications [Paper presentation]. Belgian Polymer Group (BPG) Annual Meeting, Blankenberge, Belgium.

Toussaint, F., Berger, M., Lechanteur, A., Jérôme, C., Piel, G., & Debuigne, A. (14 June 2022). Novel polyvinylpyrrolidone-based lipoplex modifiers for siRNA delivery [Poster presentation]. Bordeaux Polymer Conference, Bordeaux, France.

Toussaint, F., Berger, M., Lechanteur, A., Jérôme, C., Piel, G., & Debuigne, A. (01 June 2022). PNVP as PEG alternative for lipoplex modification in siRNA delivery application [Poster presentation]. Advanced Functional Polymers for Medecine (AFPM), Nice, France.

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D., Debuigne, A., & Piel, G. (30 March 2022). Development of innovative grafted lipoplexes using PNVP-derivatives polymers as a PEG alternative to treat cancer [Paper presentation]. 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP World Meeting), Rotterdam, Netherlands.

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D., Debuigne, A., & Piel, G. (09 March 2022). Development of innovative grafted lipoplexes using PNVP-derivatives polymers as a PEG alternative to treat cancer [Paper presentation]. 2022 Meeting of the Germany and BeNeLux & France Local Chapters of the Controlled Release Society in Aachen, Aachen, Germany.

Berger, M., Toussaint, F., Evrard, B., Jérôme, C., Lechanteur, A., Debuigne, A., & Piel, G. (02 February 2022). PNVP-polymers as a promising polyethyleneglycol (PEG) alternative onto anti-tumor lipoplexes surface [Paper presentation]. CIRM-Day, Liege, Belgium.

Berger, M., Lechanteur, A., Evrard, B., & Piel, G. (2021). Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now? International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2021.120851
Peer Reviewed verified by ORBi

Toussaint, F., Berger, M., Sanaa, B. D., Lechanteur, A., Jérôme, C., Piel, G., Mottet, D., & Debuigne, A. (27 May 2021). Polyvinylpyrrolidone compounds as PEG alternatives for lipoplex modification [Poster presentation]. Belgian Polymer Group (BPG) Annual Meeting, remote, Belgium.

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Jérôme, C., Debuigne, A., Mottet, D., Lechanteur, A., & Piel, G. (May 2021). Impact of amphiphilic N-vinyl pyrrolidone-based polymers used as PEG alternative on lipoplexes physico-chemical properties, cytotoxicity and gene delivery [Poster presentation]. Center for Interdisciplinary Research on Medicines (CIRM) Scientific Day, Liège, Belgium.

Berger, M., Toussaint, F., Pairoux, C., Evrard, B., Jérôme, C., Lechanteur, A., Debuigne, A., & Piel, G. (06 April 2021). Amphiphilic N-vinyl pyrrolidone-based polymers as PEG alternatives to avoid blood proteins adsorption around liposomes [Paper presentation]. Early Career Scientist Meeting 2021.

Berger, M., Toussaint, F., Pairoux, C., Evrard, B., Jérôme, C., Lechanteur, A., Debuigne, A., & Piel, G. (04 March 2021). Impact of amphiphilic copolymer used as PEG alternative on the formation of a protein corona around coated-liposomes encapsulating siRNA [Paper presentation]. 2021 - Virtual Local Chapter Meeting Germany and BeNeLux & France, Aachen, Germany.

Contact ORBi